A Study of LY3041658 in Participants With Skin Diseases

Status:	Active, not recruiting
Conditions:	Skin Cancer, Psoriasis, Skin and Soft Tissue Infections
Therapuetic Areas:	Dermatology / Plastic Surgery, Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	November 8, 2016
End Date:	April 2, 2019

A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases

The main purpose of this study is to investigate the safety and tolerability of the study
drug known as LY3041658 in participants with certain types of skin diseases. The study will
measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127
days for each participant, not including screening. This study is for research purposes only,
and is not intended to treat any medical condition.

Inclusion Criteria:

- Investigator confirmed diagnosis of certain skin diseases for at least 6 months.

- Active skin lesions that are not responding to standard therapies.

- Willing to undergo pre- and post-treatment skin biopsies of lesions.

Exclusion Criteria:

- Have other skin diseases that may interfere with evaluation of the specified skin disease
being studied.

We found this trial at

sites

PAREXEL-Phase 1 Baltimore Harbor Hospital Center

Baltimore, Maryland 21225

Principal Investigator: Azra Hussaini

Phone: 800-797-2448

from

Baltimore, MD